naion glp-1 Risk of Higher in Patients on Drugs for Diabetes or Weight Loss Danny D. | 👁️ Important

Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed obesity management, offering substantial weight loss and metabolic benefits

For example, estrogen signaling has been shown to enhance the anorexigenic effects of GLP-1 RAs by modulating central pathways involved in food reward, which could account for the more pronounced weight loss observed in premenopausal women [49, 50]

Initially developed for type 2 diabetes, these drugs are now widely used for obesity and cardiovascular risk reduction, with emerging applications in neurological disease [2, 3]

[DOI] [PMC free article] [PubMed] [Google Scholar] 16.Goldstein D.S., Swoboda K.J., Miles J.M., Coppack S.W., Aneman A., Holmes C., Lamensdorf I., Eisenhofer G